Literature DB >> 8820839

What to do in patients with no structural heart disease and sudden arrhythmic death?

J Brugada1, P Brugada.   

Abstract

The term "idiopathic" ventricular fibrillation is used to describe those episodes of unexpected sudden arrhythmic death due to ventricular fibrillation in patients with no demonstrable structural heart disease. Idiopathic ventricular fibrillation has been reported to account for 5-100% of all sudden arrhythmic deaths. Post mortem analysis have shown that about 80% of patients might have some kind of structural anomalies, mainly atherosclerosis, myocarditis, or right ventricular dysplasia. Follow-up of patients with idiopathic ventricular fibrillation has shown a high incidence of recurrent episodes of malignant ventricular arrhythmias. The absence of structural heart disease generally implies an excellent long-term prognosis if ventricular fibrillation can be avoided. Patients with an implantable defibrillator should have a mortality rate similar to the general population. New subsets of patients are being recognized as belonging with those previously classified as idiopathic ventricular fibrillation. More than 60 patients have been identified in different centers around the world with the so-called "right bundle branch block, ST segment elevation, and sudden death syndrome." Recurrence rate of malignant ventricular arrhythmias is very high in these patients, despite antiarrhythmic therapy. An implantable cardioverter-defibrillator seems the treatment of choice. Asymptomatic forms of the syndrome have been described. Follow-up in these asymptomatic patients has shown that some of them might become symptomatic during follow-up. Also, intermittent forms of the syndrome have been described, with transient normalization of the electrocardiogram. Administration of class I drugs in these patients unmasks the typical electrocardiographic pattern. In some of the patients previously classified as having idiopathic ventricular fibrillation, ajmaline or procainamide administration unmasks the electrocardiographic pattern of the syndrome, suggesting that its incidence may be higher than previously suspected.

Entities:  

Mesh:

Year:  1996        PMID: 8820839     DOI: 10.1016/s0002-9149(96)00505-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action.

Authors:  Claudia Kiesecker; Edgar Zitron; Sonja Lück; Ramona Bloehs; Eberhard P Scholz; Sven Kathöfer; Dierk Thomas; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-30       Impact factor: 3.000

2.  Enantiospecific total synthesis of the important biogenetic intermediates along the ajmaline pathway, (+)-polyneuridine and (+)-polyneuridine aldehyde, as well as 16-epivellosimine and macusine A.

Authors:  Wenyuan Yin; M Shahjahan Kabir; Zhijian Wang; Sundari K Rallapalli; Jun Ma; James M Cook
Journal:  J Org Chem       Date:  2010-05-21       Impact factor: 4.354

3.  Prevalence of the Brugada sign in idiopathic ventricular fibrillation and healthy controls.

Authors:  S Viskin; R Fish; M Eldar; D Zeltser; M D Lesh; A Glick; B Belhassen
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

Review 4.  Sarpagine and Related Alkaloids.

Authors:  Ojas A Namjoshi; James M Cook
Journal:  Alkaloids Chem Biol       Date:  2015-10-09

5.  Use of therapeutic hypothermia and extracorporeal life support after an unusual response to the ajmaline challenge in a patient with Brugada syndrome.

Authors:  Jacobo Moreno; Marta Magaldi; Jaume Fontanals; Lidia Gómez; Paola Berne; Antonio Berruezo; Josep Brugada
Journal:  J Cardiol Cases       Date:  2014-05-01

Review 6.  Synthesis of Bisindole Alkaloids from the Apocynaceae Which Contain a Macroline or Sarpagine Unit: A Review.

Authors:  Md Toufiqur Rahman; Veera V N Phani Babu Tiruveedhula; James M Cook
Journal:  Molecules       Date:  2016-11-14       Impact factor: 4.411

7.  Characteristics and clinical assessment of unexplained sudden cardiac arrest in the real-world setting: focus on idiopathic ventricular fibrillation.

Authors:  Victor Waldmann; Wulfran Bougouin; Nicole Karam; Florence Dumas; Ardalan Sharifzadehgan; Estelle Gandjbakhch; Vincent Algalarrondo; Kumar Narayanan; Alexandre Zhao; Denis Amet; Daniel Jost; Guillaume Geri; Lionel Lamhaut; Frankie Beganton; Bertrand Ludes; Patrick Bruneval; Isabelle Plu; Françoise Hidden-Lucet; Juliette Albuisson; Thomas Lavergne; Olivier Piot; Christine Alonso; Antoine Leenhardt; Nicolas Lellouche; Fabrice Extramiana; Alain Cariou; Xavier Jouven; Eloi Marijon
Journal:  Eur Heart J       Date:  2018-06-01       Impact factor: 29.983

Review 8.  Application of the Asymmetric Pictet-Spengler Reaction in the Total Synthesis of Natural Products and Relevant Biologically Active Compounds.

Authors:  Majid M Heravi; Vahideh Zadsirjan; Masumeh Malmir
Journal:  Molecules       Date:  2018-04-18       Impact factor: 4.411

9.  Malignant Dysrhythmias - Brugada Type 1 Pattern Formation in the Presence of Fever.

Authors:  Joshua Liroff; Karyn Gilbert; Brian S Kim
Journal:  Spartan Med Res J       Date:  2016-10-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.